Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Дефицит альфа-1-антитрипсина у взрослых

Список литературы

  1. Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respiratory Medicine 1998 Mar;92(3):367-77.
  2. Europeanlung.org/assets/files/ru/publications/alpha1-anti-trypsin-ru.pdf. Accessed 2017 December 18.
  3. Журкова Н.В., Кондакова О.Б., Строкова Т.В., Дублина Е.С., Симонова О.И, Кузьмина Л.П., Потапов А.С., Асанов А.Ю. Недостаточность α1 -антитрипсина у детей с патологией печени. Педиатрия 2008;87(3):138-41.
  4. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine 2003 Oct;168(7):818-900.
  5. Abboud RT, Ford GT, Chapman KR; Standards Committee of the Canadian Thoracic Society. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Canadian Respiratory Journal 2001 Mar-Apr;8(2):81-8.
  6. Гембицкая Т.Е. Первичная эмфизема легких, связанная с дефицитом альфа-1- антитрипсина. Клиническая медицина 1984;9:86-91.
  7. Гембицкая Т.Е., Черменский А.Г., Илькович М.М., Цампруби С. Первичная эмфизема легких у молодого мужчины, обусловленная гомозиготным дефицитом α1 - антитрипсина (генотип ZZ): перспективы организации помощи больным. Пульмонология 2014;6:115-21.
  8. Первакова М.Ю., Титова О.Н., Шумилов А.А., Лапин С.В., Суркова Е.А., Эмануэль В.Л. Особенности показателей функции внешнего дыхания у больных хронической обструктивной болезнью легких с дефицитом альфа-1-антитрипсина. Медицинский совет 2016;15:18-22.
  9. Cox DW, Woo SL, Mansfield T. DNA restriction fragments associated with α-1 antitrypsin indicate a single origin for deficiency allele PIZ. Nature 1985;316:79-81.
  10. Cox DW, Billingsley GD, Mansfield T DNA restriction site polymorphisms associated with alpha 1-antitrypsin gene. American Journal of Human Genetics 1987 Nov;41(5):891-906.
  11. Seixas S, Garcia O, Trovoada MJ, Santos MT, Amorim A, Rocha J. Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha 1-antitrypsin polymorphism. Human Genetics 2001 Jan;108(1):20-30.
  12. . Keren DF. Protein electrophoresis in clinical diagnosis. London, England: Hodder Arnold; 2003:71-7.
  13. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. The American Journal of Medicine 1988;84(6A):13-31.
  14. Cox DW. Alpha-1 antitrypsin deficiency. In: The metabolic and molecular basis of inherited disease. Scriver CR, Beadet AL, Sly WS,Valle D, editors. 7th ed. New York: McGraw-Hill; 1995:4125-58.
  15. Kamboh MI. Biochemical and genetic aspects of human serum α-1 proteinase inhibitor protein. Disease Markers 1985;3:135.
  16. Marciniuk DD, Hernandez P, Balter M, Bourbeau J, Chapman KR, Ford GT, Lauzon JL, Maltais F, O’Donnell DE, Goodridge D, Strange C, Cave AJ, Curren K, Muthuri S; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antititrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal 2012 Mar-Apr;19(2):109-16.
  17. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin alpha 1- antitrypsin Pittsburgh (358Met leads toArg), a fatal bleeding disorder. The New England Journal of Medicine 1983 Sep;309(12):694-8.
  18. Gadek JE, Fells GA, Zimmerman RL, Rennard SI, Crystal RG. Antielastase of the human alveolar structures: implications for the protease-antiprotease theory of emphysema. The Journal of Clinical Investigation 1981;68:889-98.
  19. Sandhaus RA, Turino G, Brantly ML et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult // Journal of the COPD Foundation 2016 Vol 3 N 3 P 668 – 682.
  20. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha -1- antitrypsin deficiency and COPD. The European Respiratory Journal 2013; 41(5):1042-50.
  21. Churg A., Zhou S. Wright JL. Matrix metalloproteinases in COPD. The European Respiratory Journal 2012;39(1):197-209.
  22. Osman M, Cantor JO, Roffman S, Keller S, Turino GM, Mandl I. Cigarette smoke impairs elastin resynthesis in lungs of hamsters with elastase-induced emphysema. The American Review of Respiratory Disease 1985 Sep;132(3):640-43.
  23. Morrison HM, Kramps JA, Burnett D, Stockley RA. Lung lavage fluid from patients with α-1 proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clinical Science (London) 1987 Mar;72(3):373-81.
  24. Lomas DA, Evans DL, Finch JT, Carell RW. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992 Jun;357(6379):605-7.
  25. Ranes J, Stoller JK. A review of alpha 1-antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 2005 Apr;26(2):154-66.
  26. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clinical Genetics 2003 Nov;64(5):382-97.
  27. Пузырев В.П., Савюк В.Я. Молекулярные основы и клинические аспекты недостаточности α1-антитрипсина. Пульмонология 2003;105-17.
  28. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004 May;59(5):441-5.
  29. Shin MS, Ho KJ. Bronchiectasis in patients with α-1 antitrypsin deficiency. A rare occurrence? Chest 1993 Nov;104(5):1384-6.
  30. Eden E, Mitchell D, Mehlman B, Khouli H, Mejat M, Grieco MH, Turino GM. Atopy, asthma and emphysema in patients with severe α-1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine 1997 Jul;156(1):68-74.
  31. Higgins MW, Thom T. Incidence, prevalence and mortality: intra - and inter country differences. In: Clinical epidemiology of chronic obstructive p ulmonary disease. Hensley MJ, Saunders NA, editors. New York: Marcel Dekker; 1989:23 -43.
  32. Eriksson S. Alpha-1 antitrypsin deficiency: natural course and therapeutic strategies. In: Proceedings of the Falk Symposium no. 115. Dordrecht, The Netherlands. Dordrecht/Boston/London: Kluwer Academic Publishers; 1999:307-15.
  33. Elzouki AN, Segalmark M, Mazodier P, Eriksson S. Wegener’s granulomatosis in a patient with severe PiZZ alpha 1-antitrypsin deficiency. QJM 1996 Nov;89(11):877.
  34. Mahr AD, Edberg JC, Stone JH, Hoffman GS, St Clair EW, Specks U, Dellaripa PF, Seo P, Spiera RF, Rouhani FN, Brantly ML, Merkel PA. Alpha 1-antitrypsin deficiency-related alleles Z and S and the risk of Wegener`s granulomatosis. Arthritis & Rheumatology 2010 Dec;62(12):3760-7.
  35. Yang P, Sun Z, Krowka MJ, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Archives of Internal Medicine 2008 May;168(10):1097-103.
  36. Montanelli A, Mainardi E, Pini L, Corda L, Grassi V. Alpha 1-antitrypsin deficiency and nephropathy. Nephron 2002 Jan;90(1):114-5.
  37. Rabassa AA, Schwartz MR, Ertan A. Alpha 1-antitrypsin deficiency and chronic pancreatitis. Digestive Diseases and Sciences 1995 Sep;40(9):1997-2001.
  38. Sun Z, Yang P. Role of imbalance between neutrophil elastase and α alpha 1 -antitrypsin in cancer development and progression. The Lancet Oncology 2004 Mar;5(3):182-190.
  39. Bofinger A, Hawley C, Fisher P, Daunt N, Stowasser M, Gordon R. Alpha 1-antitrypsin phenotypes in patients with renal arterial fibromuscular dysplasia. Journal of Human Hypertension 2000 Feb;14(2):91-4.
  40. Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha 1 - antitrypsin deficiency. Thorax 2003 Dec;58(12):1020 -6.
  41. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. American Journal of Respiratory and Critical Care Medicine 1998 Jul;158(1):49-59.
  42. Tanash HA, Nilsson PM, Nilsson JA, Pitulainen E. Survival in severe alpha 1-antitrypsin deficiency (PiZZ). Respiratory Research 2010 Apr;11:44
  43. Janus ED, Phillips NT, Carrell RW. Smoking, lung function and α-1 antitrypsin deficiency. Lancet 1985 Jan;1(8421):152-4.
  44. Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with pulmonary symptoms. The American Review of Respiratory Disease 1988 Aug;138(2):327-36.
  45. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of α-1 antitrypsin deficiency: results of a survey. Cleveland Clinic Journal of Medicine 1994 Nov-Dec;61(6):461-7.
  46. Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agustí A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Paré PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK. α-1 antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010 Nov;138(5):1125-32.
  47. Bornhorst J, Calderon F, Procter M, Tang W, Ashwood ER, Mao R. Genotypes and serum concentrations of human alpha-1-antitrypsin “P” protein variants in a clinical population. Journal of Clinical Pathology 2007 Oct;60(10):1124-8.
  48. Мельник С.И., Власов Н.Н., Пиневская М.В., Орлова Е.А., Старевская Е.В., Мельникова И.Ю. Дефицит альфа-1-антитрипсина у детей: описание серии случаев. Вопросы современной педиатрии 2016;15(6):619-24.
  49. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? European Journal of Gastroenterology & Hepatology 1996; Oct;8(10):989- 94.
  50. Eriksson S, Carison J, Velez R. Risks for cirrhosis and primary liver cancer in α-1 antitrypsin deficiency.The New England Journal of Medicine 1986 Mar;314(12):736-9.
  51. O’Riordan K, Blei A, Rao MS, Abecassis M. Alpha-1 antitrypsin deficiency-associated panniculitis: resolution with intravenosus α-1 antitrypsin and liver transplantation. Transplantation 1997 Feb;63(3):480-2.
  52. Aboussouan LS, Stoller JK. New developments in alpha 1-antitrypsin deficiency. Seminars in Respiratory and Critical Care Medicine 1999;20(4):301-10.
  53. Zorzetto M, Russi E, Senn O, Imboden M, Ferrarotti I, Tinelli C, Campo I, Ottaviani S, Scabini R, von Eckardstein A, Berger W, Brändli O, Rochat T, Luisetti M, Probst-Hensch N; SAPALDIA Team. SERPINA 1 gene variants in individuals from the general population with reduced alpha 1-antitrypsin concentrations. Clinical Chemistry 2008 Aug;54(8):1331-8.
  54. Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez -Frias F, Luisetti M, Bals R. Laboratory testing of individuals with severe alpha 1 -antitrypsin deficiency in three European centers. The European Respiratory Journal 2010 May;35(5):960-8.
  55. Bornhorst JA, Greene CM, Ashwood ER., Greenache DG. α1-antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest 2013 Apr;143(4):1000-8.
  56. Crowther DC, Belogrey D, Miranda E, Kinghorn KJ, Sharp LK, Lomas DA. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. European Journal of Human Genetics 2004 Mar;12(3):167-72.
  57. Nelson DR, Teckman J, Di Bisceglie AM et al. Diagnosis and management of patients with alpha 1-antitrypsin deficiency. Clin. Gastroenterol Hepatol. 2012; 10(6):575-580.
  58. Dawwas MF, Davies SE, Griffiths WJ et al. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med. 2013;187(5): 502- 508.
  59. Sandhaus RA. Alpha 1-antitrypsin deficiency: whom to test, whom to treat? Seminars in Respiratory and Critical Care Medicine 2010 Jun;31(3):343-7.
  60. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha 1-antitrypsin deficiency: relationship to lung function and health status. The European Respiratory Journal 2001 Jun;17(6):1097-104.
  61. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomography lung densitometry for monitoring emphysema alpha 1-antitrypsin deficiency. Thorax 2006 Jun;61(6):485-90.
  62. Lomas DA. Genetic predisposition to chronic obstructive pulmonary disease: advances in alpha 1-antitrypsin deficiency and serpinopathies. Clinical Medicine 2007;7(5):446-7.
  63. Tanash HA, Nilsson PM, Nilsson JA et al. Clinical course and prognosis of never-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax. 2008;63(12):1091-1095.
  64. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchinson DC, Ulrik CS, Skovgaard LT, Kok- Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J. A randomized clinical trial of α-1 antitrypsin augmentation therapy. American Journal of Respiratory and Critical Care Medicine 1999 Nov;160(5 Pt 5):1468-72.
  65. Dirksen A., Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA. Exploring the role of CT densitometry: a randomized study of augmentation therapy in alpha1-antitrypsin deficiency. The European Respiratory Journal 2009 Jun;33(6):1345-53.
  66. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1-antitrypsin deficiency: a meta-analysis. COPD 2009 Jun;6(3):177-84.
  67. Gotzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. The Cochrane Database of Systematic Reviews 2010 Jul;7(7):CD007851.
  68. McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska- Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group. Long-term efficacy and safety of alpha 1 proteinase inhibitor treatment for emphysema caused by severe alpha 1-antitrypsin deficiency: an open-label extension trial (RAPID-OLE). The Lancet Respiratory Medicine 2017 Jan;5(1):51-60.
  69. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. American Journal of Respiratory and Critical Care Medicine 1998;127(Suppl):S43-S45.
  70. Seersholm N, Wencker M, Banik N, Viskum K, Dirsken A, Kok-Jensen A, Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. The European Respiratory Journal 1997 Oct;10(10):2260-3.
  71. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. The European Respiratory Journal 1998 Feb;11(2);428-33.
  72. Barros-Tizón JC, Torres ML, Blanco I, Martínez MT; Investigators of the rEXA study group. Reduction of severe exacerbations and hospitalization-derived costs in alpha 1-antitrypsin- deficient patients treated with alpha 1-antitrypsin augmentation therapy. Therapeutic Advances in Respiratory Disease 2012 Apr;6(2):67-78.
  73. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000 Nov;118(5):1480-5.
  74. Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1- proteinase inhibitor for COPD associated with alpha 1-antitrypsin deficiency: a look at the evidence. Respiratory Research 2017 May;18(1):105.
  75. Balbi B, Ferrarotti I, Miravitlles M. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough. The European Respiratory Journal 2016 Jan:47(1):35-8.
  76. Prins J, van der Meijden B, Kraaijeenhangen RJ, Wielders JP. Inherited chronic obstructive pulmonary disease: new selective-sequencing workup for alpha1-antitrypsin deficiency identifies 2 previously unidentified null alleles. Clinical Chemistry 2008 Jan;54(1):101-7.
  77. Sandhaus RA, Turino G, Stocks J et al. Alpha-1antitrypsin augmentation therapy for Pi*MZ heterozygotes: a cautionary note. Chest 2008; 134 (4):831-834.
  78. Molloy K, Hersh CP, Morris VB et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha-1 antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014; 189(4):419-427.
  79. Tonelli AR, Rouhani F, Li N et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue bank Int J Chron Obstr Pulmon Dis. 2009 ;4:443-452
  80. Bugeja T, Gelson W, Massood A et al. A high prevalence of heterozygous alpha-1 antitrypsin deficiency in patients with advanced parenchymal liver disease. J Hepatol. 2012;56:S227.
  81. Gross B, Grebe M, Wencker M et al. New findings in PiZZ alpha-1-antitrypsindeficiency- related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenosus augmentationtherapy. Dermatology. 2009;218(4):370-375.
  82. Campos MA, Kueppers F, Stocks JM et al. Safety and pharmacokinetics of 120mg/kg versus 60 mg/kg weekly intravenous infusions of alpha -1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter , randomized, double-blind, crossover study (SPARK). COPD.2013;10(6):687-695
  83. Meyer FJ, Wencker M, Teschler H, StevelingH, Sennekamp J, Costbel U, Konietzko N. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. The European Respiratory Journal1998;12(4):996-7.
  84. Stoller JK, Fallat R, Schluchter MD, O’Brien RG, Connor JT, Gross N, O’Neil K, Sandhaus R, Crystal RG. Augmentation therapy with alpha 1 antitrypsin: patterns of use and adverse events. Chest 2003 May;123(5):1425-34.
  85. Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma – results from the ALA-ACRC low dose theophylline trial. Journal of Asthma 2007 Oct;44(8):605-8.
  86. Ngo LY, Haeberle A, Dyck-Jones J, Gelmont D, Yel L. Safety and tolerability of an intravenously administered alpha1-proteinase inhibitor at an increased infusion rate: a novel, randomized, placebo-masked, infusion rate-controlled, crossover study in healthy adults. Open Access Journal of Clinical Trials 2014 Jun;6:55 -61.
  87. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017 // www.goldcopd.com.
  88. Cassina PC, Teschler H Konietzko N, Theegarten D, Stamatis G. Two-year results after lung volume reduction surgery in alpha1-antitrypsin deficiency versus smoker’s emphysema. The European Respiratory Journal 1998 Nov;12(5):1028-32.
  89. Gelb AF, McKenna RJ, Brenner M, Fischel R, Zamel N. Lung function after bilateral lower lobe lung volume reduction surgery for alpha1-antitrypsin emphysema. The European Respiratory Journal 1999 Oct;14(4):928-33.
  90. National Emphysema Treatment Trial Research Group, Fishman A, Fessler H, Martinez F, McKenna RJ Jr, Naunheim K, Piantadosi S, Weinmann G, Wise R. Patients at high risk of death after lung-volume-reduction surgery. The New England Journal of Medicine 2001 Oct;345(15):1075-83.
  91. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. Registry of the International Society for Heart and Lung Transplantation: twelfth official report –1995. The Journal of Heart and Lung Transplantation 1995 Sep-Oct;14(5):805-15.
  92. Banga A, Gildea T, Rajeswaran J et al. The natural history of lung function after lung transplantation for alpha (1)-antitrypsin deficiency. Am J Respir Crit Care Med. 2014; 190(3):274-281.
  93. Yusen RD, Edward LB, Kucheryavaya MS et al. The registry of the International Society of Heart and Lung Transplantation; Thirty-second official adult lung and heart-lung transplantation report 2015. J Heart Lung Transplant. 2015; 34(10):1264-1277.
  94. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O’Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994 Nov;272(19):1497-505.
  95. Carpenter MJ,Strange C, Jones Y et al. Does genetic testing result in behavioral health change? Ann. Behav.Med. 2007;33(1):22-28
  96. Kuller JA, Katz VL, McCoy MC, Bristow CL. Alpha-1 antitrypsin deficiency and pregnancy. American Journal of Perinatology 1995 Sep;12(5):303-5.
  97. Atkinson AR. Pregnancy and alpha-1 antitrypsin deficiency. Postgraduate Medical Journal 1987 Sep;63(743):817-20.
  98. Geisler CF, Buehler JH, Depp R. Alpha-1 antitrypsin deficiency: severe obstructive lung disease and pregnancy. Obstetrics & Gynecology 1977;49(1):31-4.
  99. Hall JC, Tarala RA, Hall JL, Mander J. A multivariate analysis of the risk of pulmonary complications after laparotomy. Chest 1991 Apr;99(4):923-7.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*